LDL (mg/dl) 111.2 [+ or -] 39.8 HbA1c (%) 8.6 [+ or -] 2.3 FPG (mg/dl) 179.3 [+ or -] 72.1 PPPG
(mg/dl) 267.9 [+ or -] 111.9 S.Uric Acid (mg/dl) 4.8 [+ or -] 1.4 (b) Demographic and biochemical features of patients studied (categorical variables) Variable Frequency (%) Sex Male 742 (64.4) Female 410 (35.6) Smoker 84 (7.3) Alcohol 183 (15.9) Diabetes >2 yr 447 (38.8) Known Hypertension 355 (30.8) Uncontrolled systolic BP 670 (58.2) Uncontrolled diastolic BP 172 (14.9) Dyslipidemia 316 (27.5) Known Hypothyroidism 96 (8.4) Abdominal obesity 1059 (91.9) Anemia 307 (26.6) ESR>20 mm/hr 390 (33.9) S.
Using the hospitalized multidisciplinary approach including the appropriate dietary- and exercise-therapies, all patients of both treatment groups presented with significant improvements in HbA1c (mean [+ or -] SD; pretreatment 8.8 [+ or -] 1.0% to posttreatment 7.9 [+ or -] 0.8%, P < 0.001), FPG (151.0[+ or -]31.6 to 123.5 [+ or -] 35.1 mg/dL, P < 0.01), PPPG
(251.2 [+ or -] 64.2 to 153.1 [+ or -] 45.5 mg/dL, P < 0.001), and BMI (26.6 [+ or -] 2.7 to 25.6 [+ or -] 2.5, P < 0.001).
However, resistance to insulin therapy is often ascribed to factors such as fear of hypoglycaemia and weight gain.4 Furthermore, the variability in the pharmacological profile of human insulin preparations, such as biphasic human insulin 30 (BHI 30), often results in unpredictable effects on glycaemic control.5 Hence, the insulin analogue, biphasic insulin aspart 30 (BIAsp 30), was designed with an aim to overcome these limitations and provide adequate glycaemic control by regulating fasting plasma glucose (FPG) and post-prandial plasma glucose (PPPG) levels.6
Glucose control was evaluated using changes in HbA1c levels, FPG and post-breakfast PPPG from baseline to Week 24.
The paired t-test was used to analyse the changes in HbA1c, FPG and PPPG from baseline to Week 24.
Following 24 weeks of BIAsp 30 therapy, significant improvements in HbA1c (-1.7+-0.9%, p less than 0.001), FPG (-61.6+-47.8 mg/dL, p less than 0.001) and PPPG (-95.2+-48.0 mg/dL, p less than 0.001) were observed (Figure).
FPG: fasting plasma glucose, PPPG: postprandial plasma glucose, HbA1C: haemoglobin A1C, GFR: estimated glomerular filtration rate, CVD: cardiovascular disease, DKD: diabetic kidney disease, OHI-S: oral hygiene index-simplified, CAL: clinical attachment loss, BOP: bleeding on probing, PPD: pocket probing depth.
In present study, glycaemic indices FPG, PPPG, HbA1c were higher in subjects with T2DM with chronic periodontitis than those without.
shows that difference in FPG and PPPG, both were highly significant with P value <0.001 in the study group as compared to the control group.
These include assessment of glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPPG).
RESULTS: Mean fasting plasma glucose (FPG) was 130.30+6 (SD), mean post prandial plasma glucose (PPPG
) was 191.76+10.99 (SD), mean HbA1c was 8.2+2.(SD), mean body mass index (BMI) was 25.+25+3.88 (SD) and mean serum homocysteine level was found as 15.12+6.68 uGu/ml (SD), when all 80 subjects taken together.
There was no significant difference in FPG (118.8 [+ or -] 59.3) and PPPG
(158.4 [+ or -] 71.9) in CKD patients with Hemodialysis compared to FPG (115.0 [+ or -] 25.9) and PPPG
(160.8 [+ or -] 48.0) in CKD patients without hemodialysis.